97 related articles for article (PubMed ID: 32894664)
1. Strong Correlation between the Expression of CHEK1 and Clinicopathological Features of Patients with Multiple Myeloma.
Liu XP; Huang Q; Yin XH; Meng XY; Cao Y; Yan XH; He L
Crit Rev Eukaryot Gene Expr; 2020; 30(4):349-357. PubMed ID: 32894664
[TBL] [Abstract][Full Text] [Related]
2. Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.
Yang Q; Li K; Li X; Liu J
Int J Med Sci; 2020; 17(14):2063-2076. PubMed ID: 32922167
[No Abstract] [Full Text] [Related]
3. Identification potential biomarkers and therapeutic agents in multiple myeloma based on bioinformatics analysis.
Wang XG; Peng Y; Song XL; Lan JP
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):810-7. PubMed ID: 27010134
[TBL] [Abstract][Full Text] [Related]
4. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.
Gu C; Wang W; Tang X; Xu T; Zhang Y; Guo M; Wei R; Wang Y; Jurczyszyn A; Janz S; Beksac M; Zhan F; Seckinger A; Hose D; Pan J; Yang Y
Mol Cancer; 2021 Jun; 20(1):84. PubMed ID: 34090465
[TBL] [Abstract][Full Text] [Related]
5. RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.
Yang X; Pan Y; Qiu Z; Du Z; Zhang Y; Fa P; Gorityala S; Ma S; Li S; Chen C; Wang H; Xu Y; Yan C; Ruth K; Ma Z; Zhang J
Clin Cancer Res; 2018 Apr; 24(7):1629-1643. PubMed ID: 29326282
[No Abstract] [Full Text] [Related]
6. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of a 9-Gene Prognostic Signature in Patients With Multiple Myeloma.
Liu XP; Yin XH; Meng XY; Yan XH; Wang F; He L
Front Oncol; 2018; 8():615. PubMed ID: 30671382
[No Abstract] [Full Text] [Related]
8. HLA-DPA1 gene is a potential predictor with prognostic values in multiple myeloma.
Yang J; Wang F; Chen B
BMC Cancer; 2020 Sep; 20(1):915. PubMed ID: 32972413
[TBL] [Abstract][Full Text] [Related]
9. Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM).
Zhong L; Hao P; Zhang Q; Jiang T; Li H; Xiao J; Li C; Luo L; Xie C; Hu J; Wang L; Liu Y; Shi Y; Zhang W; Gong B
Elife; 2022 Oct; 11():. PubMed ID: 36315425
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma.
Li J; Liu X; Cui Z; Han G
Med Sci Monit; 2020 Jun; 26():e922070. PubMed ID: 32578582
[TBL] [Abstract][Full Text] [Related]
11. Screening key genes and signaling pathways in colorectal cancer by integrated bioinformatics analysis.
Yu C; Chen F; Jiang J; Zhang H; Zhou M
Mol Med Rep; 2019 Aug; 20(2):1259-1269. PubMed ID: 31173250
[TBL] [Abstract][Full Text] [Related]
12. Screening and Identification of Key Biomarkers in Inflammatory Breast Cancer Through Integrated Bioinformatic Analyses.
Wu J; Lv Q; Huang H; Zhu M; Meng D
Genet Test Mol Biomarkers; 2020 Aug; 24(8):484-491. PubMed ID: 32598242
[No Abstract] [Full Text] [Related]
13. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis.
Wang L; Qu J; Liang Y; Zhao D; Rehman FU; Qin K; Zhang X
Thorac Cancer; 2020 Apr; 11(4):851-866. PubMed ID: 32059076
[TBL] [Abstract][Full Text] [Related]
15. Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.
Alcaraz-Sanabria A; Nieto-Jiménez C; Corrales-Sánchez V; Serrano-Oviedo L; Andrés-Pretel F; Montero JC; Burgos M; Llopis J; Galán-Moya EM; Pandiella A; Ocaña A
Mol Cancer Ther; 2017 Nov; 16(11):2552-2562. PubMed ID: 28847989
[TBL] [Abstract][Full Text] [Related]
16. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
17. Identification of gene modules and hub genes in colon adenocarcinoma associated with pathological stage based on WGCNA analysis.
Wang H; Liu J; Li J; Zang D; Wang X; Chen Y; Gu T; Su W; Song N
Cancer Genet; 2020 Apr; 242():1-7. PubMed ID: 32036224
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients.
Ebili HO; Iyawe VO; Adeleke KR; Salami BA; Banjo AA; Nolan C; Rakha E; Ellis I; Green A; Agboola AOJ
Mol Diagn Ther; 2018 Feb; 22(1):79-90. PubMed ID: 29075961
[TBL] [Abstract][Full Text] [Related]
19. The Identification of Key Gene Expression Signature and Biological Pathways in Metastatic Renal Cell Carcinoma.
Bao L; Zhao Y; Liu C; Cao Q; Huang Y; Chen K; Song Z
J Cancer; 2020; 11(7):1712-1726. PubMed ID: 32194783
[No Abstract] [Full Text] [Related]
20. Identification of key candidate genes and pathways in anaplastic thyroid cancer by bioinformatics analysis.
Ding YG; Ren YL; Xu YS; Wei CS; Zhang YB; Zhang SK; Guo CA
Am J Otolaryngol; 2020; 41(3):102434. PubMed ID: 32093976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
